2018

Janssen U.S. Transparency Report

Our third annual Janssen U.S. Transparency Report reflects our commitment to responsible business practices that put patients first, including how we invest our resources, price our medicines, and help people who need our medicines get access to them.
Open Video
“We believe enhancing transparency is a positive step toward a more sustainable, results-based health system that delivers greater access to care at a more manageable cost. As our third annual U.S. Transparency Report shows, the average net price of our medicines in the U.S. has decreased for two years in a row, and we have maintained our significant investment in discovering and developing transformational medicines for patients facing some of the world’s most challenging diseases. This year, our report also details our plan to include list price and typical patient out-of-pocket costs in our U.S. pharmaceutical TV advertising.”
Scott White Company Group Chairman North America Pharmaceuticals

5 Things to Know about our 2018 U.S. Transparency Report